-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FHND-9041 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.FHND-9041 in Non-Small Cell Lung Cancer Drug Details:FHND-9041 is under development for the treatment of T790...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HM-97662 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HM-97662 in Non-Small Cell Lung CancerDrug Details:HM-97662 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MVXONCO-1 in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MVXONCO-1 in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: MVXONCO-1 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MVXONCO-1 in Chordoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MVXONCO-1 in Chordoma Drug Details: MVXONCO-1 is under development for the treatment of lung carcinoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MVXONCO-1 in Laryngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MVXONCO-1 in Laryngeal Cancer Drug Details: MVXONCO-1 is under development for the treatment of lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MVXONCO-1 in Pharyngeal Neoplasm
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MVXONCO-1 in Pharyngeal Neoplasm Drug Details: MVXONCO-1 is under development for the treatment of lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ranibizumab Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Ranibizumab Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration Drug Details: Ranibizumab biosimilar (CHS-3351)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MVXONCO-1 in Oral Cavity (Mouth) Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MVXONCO-1 in Oral Cavity (Mouth) Cancer Drug Details: MVXONCO-1 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Monoclonal Antibody Conjugate 3 To Target Egfr For Oncology in Malignant Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Monoclonal Antibody Conjugate 3 To Target Egfr For Oncology in Malignant Mesothelioma Drug Details:Monoclonal antibody conjugate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAS-117 in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TAS-117 in Breast Cancer Drug Details: TAS-117 is under development for the treatment of solid tumors...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.